↓ Skip to main content

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

Overview of attention for article published in Cochrane database of systematic reviews, July 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
9 tweeters
wikipedia
1 Wikipedia page
f1000
1 research highlight platform

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
153 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Published in
Cochrane database of systematic reviews, July 2013
DOI 10.1002/14651858.cd006910.pub2
Pubmed ID
Authors

Theresa A Lawrie, Andrew Bryant, Alison Cameron, Emma Gray, Jo Morrison

Abstract

Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore maintaining quality of life with effective symptom control is the main purpose of treatment. Drug treatment of relapsed disease is directed by the platinum-free interval: relapsed platinum-sensitive disease is usually re-treated with platinum-based therapy and platinum-resistant disease challenged with non-platinum drugs. However, the side-effects of chemotherapy agents may be severe and optimal treatment regimens are unclear. Pegylated liposomal doxorubicin (PLD), which contains a cytotoxic drug called doxorubicin hydrochloride is one of several treatment modalities that may be considered for single-agent treatment of relapsed EOC, or used in combination with other drugs.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 153 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Spain 1 <1%
Ecuador 1 <1%
Canada 1 <1%
Unknown 148 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 26 17%
Researcher 21 14%
Student > Ph. D. Student 18 12%
Student > Bachelor 16 10%
Other 12 8%
Other 24 16%
Unknown 36 24%
Readers by discipline Count As %
Medicine and Dentistry 68 44%
Nursing and Health Professions 11 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Agricultural and Biological Sciences 5 3%
Psychology 5 3%
Other 19 12%
Unknown 39 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2020.
All research outputs
#2,420,473
of 15,807,984 outputs
Outputs from Cochrane database of systematic reviews
#5,075
of 11,294 outputs
Outputs of similar age
#24,641
of 158,235 outputs
Outputs of similar age from Cochrane database of systematic reviews
#56
of 164 outputs
Altmetric has tracked 15,807,984 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,294 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.5. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 158,235 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 164 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.